GSK to spend up to $1.3 billion on Hutchmed's dual-target cancer therapy

GSK announced a deal to acquire the majority rights to Hutchmed's experimental therapy HMPL-A830. The agreement includes an upfront payment of $110 million and potential milestone and royalty payments that could bring the total value to about $1.3 billion.

HMPL-A830 is described as an antibody‑targeted therapeutic conjugate that links an antibody against EGFR with a small‑molecule payload that blocks KRAS. Hutchmed says the combination shows synergistic anti‑tumor activity and durable responses in preclinical studies.

If the therapy moves into clinical trials as planned later this year, it could expand the range of cancers treatable with antibody‑drug conjugate technology, which has become a key pillar of oncology drug development.

The transaction marks GSK's latest push into the Chinese market and reflects its strategy to invest in novel oncology platforms that address multiple tumor drivers.